|
Reykjavik, Iceland, December 17, 2003
|
|
|
|
Simple gene expression assays used in clinical
trials predicted response to common asthma and hypertension drugs
with an average accuracy of 85%
|
|
|
| |
|
Reykjavik, Iceland, December 11, 2003
|
|
|
|
Common forms of these genes confer significant
predisposition to obesity
|
|
|
| |
|
Reykjavik, Iceland, November 17, 2003
|
|
|
|
|
|
|
| |
|
Reykjavik, Iceland, November 13, 2003
|
|
|
|
|
|
|
| |
|
Reykjavik, Iceland, November 10, 2003
|
|
|
|
|
|
|
| |
|
Reykjavik, Iceland, November 3, 2003
|
|
|
|
Variations in the BMP2 gene triple risk for
osteoporosis; deCODE is applying these findings to develop a DNA-based
test to enable effective prevention of the disease
|
|
|
| |
|
Reykjavik, Iceland, October 29, 2003
|
|
|
|
Higher revenues, streamlined cost structure
drive positive cashflow from operations; Strengthened cash position
bolsters resources for product development
|
|
|
| |
|
Reykjavik, Iceland, October 27, 2003
|
|
|
|
|
|
|
| |
|
Reykjavik, Iceland, and Basel, Switzerland,
October 17, 2003
|
|
|
|
DNA-based diagnostics applying these findings
may enable more targeted, individualized prevention strategies
|
|
|
| |
|
Reykjavik, Iceland, September 30, 2003
|
|
|
|
deCODE has discovered a gene with certain
variations that predispose to obesity and others that predispose
to thinness
|
|
|
| |
|
September 22, 2003
|
|
|
|
deCODE has identified both at-risk and pretective
haplotypes within the PDE4D gene, and is applying its findings
to develop novel drugs and diagnostics
|
|
|
| |
|
Reykjavik, Iceland, September 17, 2003
|
|
|
|
|
|
|
| |
|
Reykjavik, Iceland, August 13, 2003
|
|
|
|
Company accelerating product development
efforts, building revenues with significantly improved cost structure;
net loss down 48%, cash strength conserved
|
|
|
| |
|
Reykjavik, Iceland, August 7, 2003
|
|
|
|
|
|
|
| |
|
Reykjavik, Iceland, July 1, 2003
|
|
|
|
Diagnostics milestones, progress towards
the clinic in drug discovery, strong cash position underscore execution
of product-driven strategy
|
|
|
| |
|
Reykjavik, Iceland, May 14, 2003
|
|
|
|
Product development and service businesses
build on solid revenue base, cost reduction strategy yielding results
|
|
|
| |
|
Reykjavik, Iceland, May 7, 2003
|
|
|
|
|
|
|
| |
|
Reykjavik, Iceland, April 8, 2003
|
|
|
|
RoboHTC is an integrated hardware and informatics
solution for designing, generating, imaging, storing and annotating
protein crystallization experiments
|
|
|
| |
|
Reykjavik, Iceland, March 31, 2003
|
|
|
|
New alliances, drug discovery capabilities
position deCODE to create growing, product-driven value from its
breakthroughs in human genetics
|
|
|
| |
|
Reykjavik, Iceland, March 25, 2003
|
|
|
|
|
|
|
| |
|
Reykjavik, Iceland, March 3, 2003
|
|
|
|
|
|
|
| |
|
Reykjavik, Iceland, and Libertyville, Illinois,
February 12, 2003
|
|
|
|
deCODE enlisted to carry out the latest stage
in one of the most aggressive drug development drives ever undertaken
by a family-based patients' organization
|
|
|
| |
|
Reykjavik, Iceland, and Cambridge, Massachusetts,
January 31, 2003
|
|
|
|
Vertex will leverage deCODE's ability to
conduct pharmacogenomic analysis in parallel with clinical trials
|
|
|
| |
|
Reykjavik, Iceland, and Armonk, N.Y., January
23, 2003
|
|
|
|
Initiative to link knowledge about the human
genome and disease also aims to improve diagnostic and treatment
decisions
|
|
|
| |
|
Reykjavik, Iceland, and Basel, Switzerland,
January 9, 2003
|
|
|
|
The companies will apply these discoveries
to create a DNA-based diagnostic test to aid effective prevention
of the disease
|
|
|
| |
|
Reykjavik, Iceland, January 6, 2003
|
|
|
|
|
|
|
| |
